Anti-Human CD22 Recombinant Antibody (Epratuzumab) (CAT#: TAB-176)

Recombinant monoclonal antibody to CD22. Epratuzumab is a humanized monoclonal antibody. Potential uses may be found in oncology and in treatment of inflammatory autoimmune disorders, such as lupus (SLE).


Specific Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Fc Engineering:
  • Published Data
  • Tested Data
  • Gene Expression
  • Datasheet
  • MSDS
  • COA
Activ

Figure 1 Epratuzumab measured KD on Biacore.

Figure 1 Epratuzumab measured KD on Biacore.

Affinity of epratuzumab for CD22 ECD was determined by measuring binding of free epratuzumab to a Biacore column after competition with soluble CD22 ECD (A). B, kinetics of direct epratuzumab binding (0.8–200 nm) over a CD22 ECD surface, showing a very slow off rate. Cloned, Chinese hamster ovary-expressed, and purified CD22 ECD (as shown in panel C) on the blotted membrane with rabbit anti-CD22 was used for molecular characterization of epratuzumab binding.

Carnahan, J., Wang, P., Kendall, R., Chen, C., Hu, S., Boone, T.,... & Elliott, G. (2003). Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties. Clinical Cancer Research, 9(10), 3982s-3990s.

WB

Figure 2 Epratuzumab induces phosphorylation of CD22.

Figure 2 Epratuzumab induces phosphorylation of CD22.

Daudi or Ramos cell lines were treated for 15 min at 37°C with a saturating dose of epratuzumab, epratuzumab and a cross-linker, or a B cell receptor activator, anti-IgM. Cells were lysed and CD22 was immunoprecipitated to examine the signaling potential of epratuzumab, using phosphotyrosine-specific antibody (top). To ensure equal CD22 loading, immunoblots were stripped and reprobed with a polyclonal rabbit anti-CD22 (bottom) (see "Materials and Methods").

Carnahan, J., Wang, P., Kendall, R., Chen, C., Hu, S., Boone, T.,... & Elliott, G. (2003). Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties. Clinical Cancer Research, 9(10), 3982s-3990s.

IF

Figure 3 FITC-epratuzumab direct internalization.

Figure 3 FITC-epratuzumab direct internalization.

FITC-labeled epratuzumab was used to label Daudi tumor cells on ice for 30 min. Cells were subsequently washed and allowed to incubate for an additional 60 min at either 4°C (left) or 37°C (right). CD22 internalization is evident from capping and punctate staining of endocytic vesicles (arrows) visible in cells incubated at 37°C.

Carnahan, J., Wang, P., Kendall, R., Chen, C., Hu, S., Boone, T.,... & Elliott, G. (2003). Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties. Clinical Cancer Research, 9(10), 3982s-3990s.

FC

Figure 4 CD22 internalization as measured by flow cytometry using a noncompeting anti-CD22 antibody.

Figure 4 CD22 internalization as measured by flow cytometry using a noncompeting anti-CD22 antibody.

Daudi cells were incubated in the presence of 5 μg/ml epratuzumab (Emab) for 20 h at 37°C and analyzed by flow cytometry for CD22 internalization (A) as observed by an apparent lowering of cell surface CD22, measured with the FITC-S-HCL1 anti-CD22 monoclonal antibody. B, evidence that adding increasing epratuzumab concentrations together with FITC-labeled S-HCL1 did not result in lowering the signal observed with FITCH-SCI1 alone (solid blue trace). This confirms that these two anti-CD22 monoclonal antibodies recognize distinct and noncompeting epitopes on CD22 (FACS using the Daudi cell line). FSC-H, forward scatter; SSC-H, side scatter.

Carnahan, J., Wang, P., Kendall, R., Chen, C., Hu, S., Boone, T.,... & Elliott, G. (2003). Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties. Clinical Cancer Research, 9(10), 3982s-3990s.

FC

Figure 5 Quantification of CD22 receptor density after epratuzumab treatment.

Figure 5 Quantification of CD22 receptor density after epratuzumab treatment.

Daudi lymphoma cells (106 cells/ml) were incubated with increasing concentrations of epratuzumab in RPMI supplemented with 10% FBS for 1 h at 37°C. Cells were then washed with cold PBS and immediately analyzed by FACS for CD22 receptor quantification as described. The resulting CD22 density as measured with QuantiBRITE beads and H-SCL1 PE labeled is shown as a percentage of total CD22 on untreated cells (100%). At 5 μg/ml, cells have reached the maximum level of internalization, which is 70% in this experiment.

Carnahan, J., Wang, P., Kendall, R., Chen, C., Hu, S., Boone, T.,... & Elliott, G. (2003). Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties. Clinical Cancer Research, 9(10), 3982s-3990s.

Inter

Figure 6 Epratuzuma-induced CD22 internalization kinetics.

Figure 6 Epratuzuma-induced CD22 internalization kinetics.

Daudi cells and tonsil-derived mononuclear cells were incubated with increasing incubation time in the presence of 25 μg/ml epratuzumab/ At the end of each time point, cells were immunostained with anti-CD22 H-SCL1-PE only (Daudi) or anti-CD19-FITC and anti-CD22-PE (tonsils) for receptor quantification, as described. At early time points, the Daudi cell line is more efficacious in receptor internalization. After prolonged treatment, however (>18 h), no internalization efficiency difference between cell lines and primary cells could be observed.

Carnahan, J., Wang, P., Kendall, R., Chen, C., Hu, S., Boone, T.,... & Elliott, G. (2003). Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties. Clinical Cancer Research, 9(10), 3982s-3990s.


Specifications

  • Immunogen
  • Human tonsil lymphocytes.
  • Host Species
  • Mouse
  • Derivation
  • Humanized (from mouse)
  • Type
  • IgG1
  • Specificity
  • Tested positive against native human antigen.
  • Species Reactivity
  • Human
  • Applications
  • IF, IP, Neut, FuncS, ELISA, FC, ICC, Activ, WB
  • Trade name
  • LymphoCide
  • CAS
  • 205923-57-5
  • Generic Name
  • Epratuzumab
  • DrugBank
  • DB04958
  • UNII
  • 3062P60MH9
  • Related Disease
  • B cell lymphoma

Product Property

  • Purity
  • >95.0%, determined by analysis by RP-HPLC & analysis by SDS-PAGE.
  • Storage
  • Store at 4°C for up to 3 months. For longer term storage aliquot into small volumes and store at -20°C.

Applications

  • Application Notes
  • The CD22 antibody has been reported in applications of IF, IP, Neut, FuncS, ELISA, FC, ICC, Activ, WB.

Target

  • Alternative Names
  • Epratuzumab;LymphoCide;205923-57-5;AMG 412;hLL2;DB04958CD22;CD22 molecule;CD22 antigen;B-cell receptor CD22;sialic acid binding Ig like lectin 2;SIGLEC 2;SIGLEC2;BL-CAM;T-cell surface antigen Leu-14;B-lymphocyte cell adhesion molecule;sialic acid binding

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "Epratuzumab"

Afuco™ Anti-CD22 ADCC Recombinant Antibody (Epratuzumab), ADCC Enhanced
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to CD22. Epratuzumab is a humanized monoclonal antibody. Potential uses may be found in oncology and in treatment of inflammatory autoimmune disorders, such as lupus (SLE).

See other products for "CD22"

Humanized Antibody

CAT Product Name Application Type
TAB-198 Humanized Anti-CD22 Recombinant Antibody (clone Inotuzumab) ELISA, FC, IP, FuncS, IF, Neut, ICC Humanized (from mouse) IgG4, κ
TAB-899 Humanized Anti-CD22 Recombinant Antibody (clone Pinatuzumab) FC, IP, ELISA, Neut, FuncS, IF, ICC Humanized (from mouse) IgG1, κ
TAB-1725CL-F(E) Human Anti-CD22 Recombinant Antibody; Fab Fragment (TAB-1725CL-F(E)) Block, Cyt, ELISA, FuncS Humanized Fab
TAB-1729CL-F(E) Human Anti-CD22 Recombinant Antibody; Fab Fragment (TAB-1729CL-F(E)) IF, FC Humanized Fab
TAB-002LC-S(P) Anti-Human CD22 Recombinant Antibody scFv Fragment (VM1000) ELISA, SPR Humanized antibody

Immunotoxin

CAT Product Name Application Type
AGTO-G077S Anti-CD22 immunotoxin RFB4 (IgG)-Sap Cytotoxicity assay, Function study
AGTO-L048E anti-CD22 immunotoxin RFB4 (scFv)-PE Cytotoxicity assay, Functional assay
AGTO-L048D anti-CD22 immunotoxin RFB4 (scFv)-DT Cytotoxicity assay, Functional assay
AGTO-L048G anti-CD22 immunotoxin RFB4 (scFv)-Gel Cytotoxicity assay, Functional assay
AGTO-L048R anti-CD22 immunotoxin RFB4 (scFv)-RTA Cytotoxicity assay, Functional assay

Fab Glycosylation

CAT Product Name Application Type
Gly-001LC Recombinant Anti-Human CD22 Antibody (Fab glycosylation) ELISA, FC Mouse antibody

Fc Glycosylation

CAT Product Name Application Type
Gly-111LC Recombinant Anti-Human CD22 Antibody (Fc glycosylation) ELISA Chimeric antibody (mouse/human)

Blocking Antibody

CAT Product Name Application Type
NEUT-315CQ Rat Anti-CD22 Recombinant Antibody (clone 2D6) Block Rat IgG1, κ

Rabbit Monoclonal Antibody

CAT Product Name Application Type
MOR-0545 Hi-Affi™ Rabbit Anti-CD22 Recombinant Antibody (clone DS545AB) IP, WB Rabbit IgG

Recombinant Antibody

ADCC Enhanced Antibody

CAT Product Name Application Type
AFC-TAB-176 Afuco™ Anti-CD22 ADCC Recombinant Antibody (Epratuzumab), ADCC Enhanced IF, IP, Neut, FuncS, ELISA, FC ADCC enhanced antibody
AFC-TAB-198 Afuco™ Anti-CD22 ADCC Recombinant Antibody (Inotuzumab), ADCC Enhanced ELISA, FC, IP, FuncS, IF, Neut ADCC enhanced antibody

Customer Reviews and Q&As

Submit a review or a question
There are currently no Customer reviews or questions for TAB-176. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.

For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

© 2024 Creative Biolabs.
  • 0
  • 0
Cart

    Go to compare